Newsletter Signup | Join Community
Men with prostate cancer have genomic defects that can be targeted with Lynparza and should undergo genomic testing.
Xtandi® + Zytiga® does not improve survival in advanced prostate cancer compared to Xtandi alone.
Erleada prolongs survival in non-metastatic Castration-resistant Prostate Cancer and for those with metastatic disease.
Initial results of KEYNOTE 365 study of Keytruda immunotherapy in prostate cancer released at 2019 ASCO
Xtandi® superior to non-steroidal anti-androgens and improves survival in all phases of advanced prostate cancer.
Urologists are one of the experts that treat prostate cancer with surgery or prostatectomy. How do you choose one?
Oncotype DX - Prostate The Beginning of Individualized Treatment
Studies demonstrate that Zytiga improves outcomes in men with newly diagnosed and ADT resistant prostate cancer.
UCLA Doctors Report that Five Days Sterotactic Radiation Therapy as Effective as 45 Days
Taxotere ineffective when used to treat early stage androgen sensitive prostate cancer.
Harvard Study on Statins lowering risk of prostate cancer. …
Tell Your PSA Story: Has the PSA test helped in your prostate cancer journey? Its Prostate Cancer…